drugset / Trial / NCT06213311
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
Phase 2
Recruiting
40 enrolled
M.D. Anderson Cancer Center
Genentech, Inc. · collabKite, A Gilead Company · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Timeline
- Start
- 2024-05-07
- Primary completion
- 2027-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |